StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$69.06−5.12 (-6.90%)

Close on Nov 18, 2026Market cap $1.02BP/E –Yield –

Inhibrx Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Inhibrx Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $100.43M, down 17.0% year over year. For fiscal 2025 it was $113.03M, down 44.5% from the year before. The highest annual figure on record is $203.74M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$113.03M-44.5%
FY2024Dec 31, 2024$203.74M+6.3%
FY2023Dec 31, 2023$191.64M+73.9%
FY2022Dec 31, 2022$110.19M+54.2%
FY2021Dec 31, 2021$71.44M-2.8%
FY2020Dec 31, 2020$73.50M+53.4%
FY2019Dec 31, 2019$47.91M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$25.97M-9.0%
Q2 FY2026Jun 30, 2026$23.90M+7.3%
Q1 FY2026Mar 31, 2026$25.22M-31.6%
Q4 FY2025Dec 31, 2025$25.35M-24.0%
Q3 FY2025Sep 30, 2025$28.54M-26.6%
Q2 FY2025Jun 30, 2025$22.27M-67.1%
Q1 FY2025Mar 31, 2025$36.88M-42.2%
Q4 FY2024Dec 31, 2024$33.37M-59.4%
Q3 FY2024Sep 30, 2024$38.89M+2.2%
Q2 FY2024Jun 30, 2024$67.63M+98.3%
Q1 FY2024Mar 31, 2024$63.85M+70.8%
Q4 FY2023Dec 31, 2023$82.09M+169.6%
Q3 FY2023Sep 30, 2023$38.06M+52.6%
Q2 FY2023Jun 30, 2023$34.11M+14.0%
Q1 FY2023Mar 31, 2023$37.39M+50.2%
Q4 FY2022Dec 31, 2022$30.45M+63.6%
Q3 FY2022Sep 30, 2022$24.93M+34.9%
Q2 FY2022Jun 30, 2022$29.91M+67.1%
Q1 FY2022Mar 31, 2022$24.90M+51.4%
Q4 FY2021Dec 31, 2021$18.62M+5.4%
Q3 FY2021Sep 30, 2021$18.49M-6.8%
Q2 FY2021Jun 30, 2021$17.90M-5.6%
Q1 FY2021Mar 31, 2021$16.44M-3.4%
Q4 FY2020Dec 31, 2020$17.67M+43.8%
Q3 FY2020Sep 30, 2020$19.84M+55.2%
Q2 FY2020Jun 30, 2020$18.97M–
Q1 FY2020Mar 31, 2020$17.02M–
Q4 FY2019Dec 31, 2019$12.28M–
Q3 FY2019Sep 30, 2019$12.79M–

More Inhibrx Biosciences figures

See a number that looks wrong?